- Date: November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund. GlyCardial is a spin-off from the Catalan Institute of Cardiovascular Sciences (ICCC), which participated in CaixaImpulse 2015 through the Apo J-Glyc project.
The project was named after the protein identified by the ICCC team as a biomarker for early myocardial ischemia diagnosis, and, as in most heart conditions, quick detection is crucial when treating the disease. Caused by a lack of blood supply in the heart, myocardial ischemia is the most common cardiovascular issue, and if it becomes persistent it can end up causing a heart attack.
Led by Judit Cubedo (CEO) and Lina Badimon (CSO), GlyCardial Diagnostics aims to develop a point-of-care device that can quickly detect abnormal levels of Apo J-Glyc protein in the blood. This device could be used in ambulances for example, and would provide an accurate test to allow healthcare decisions to be made quickly. The funds will allow the company to clinically validate the new blood test and to apply for the CE certification mark over the next three years, which would allow the device to be sold in the European Economic Area.
More programme highlights
September 12, 2018
On 6 September, CaixaForum Barcelona hosted a Pitch Day for the projects that took part in the CaixaImpulse 2017.
September 07, 2018
A diagnostic kit for septicaemia and a medical device to reduce hospital-acquired infections are some examples of the projects featured in the 2018 programme.
August 30, 2018
From 3-7 September, CaixaImpulse will host the first of four weeks of training available to this year’s participants.